Rule 10b5-1 Arrangement Modified [Flag] N/A Non-Rule 10b5-1 Arrangement Modified [Flag] N/A Total current assets Total assets Total current liabilities Total liabilities Class of Stock [Axis] Total stockholders’ equity Balance Balance Total liabilities and stockholders’ equity Total operating expenses Loss from operations Total other income (expenses) Net income (loss) Net income (Loss) Net income (loss) Net comprehensive income (loss) Net income (loss) Balance (in Shares) Balance (in Shares) Equity Components [Axis] Net cash used in investing activities Net cash provided by financing activities Net increase (decrease) in cash and cash equivalents Cash and cash equivalents at the beginning of the period Cash and cash equivalents at the end of the period Organization and Description of Business [Abstract] Summary of Significant Accounting Policies [Abstract] Cash and Cash Equivalents [Axis] Liability Class [Axis] Fair Value Hierarchy and NAV [Axis] Fair value opening balance Fair value ending balance Warrant liability Cash, Cash Equivalents, and Marketable Securities [Abstract] Asset Class [Axis] Significant Agreements [Abstract] Balance Sheet Components [Abstract] Schedule of Prepaid Expenses and Other Current Assets [Abstract] Total Prepaid expenses and other current assets Long-Lived Asset, Class [Axis] Net Property and equipment, net Schedule of Accounts Payable [Abstract] Total Accounts payable Schedule of Accrued Liabilities [Abstract] Total Accrued liabilities Operating Lease [Abstract] Schedule of Maturities of Lease Liabilities [Abstract] Total lease payments Present value of lease liability Lease liability Schedule of Remaining Lease Term and Discount Rates [Abstract] Commitments and Contingencies [Abstract] Stockholders’ Equity [Abstract] Number of Shares Underlying Outstanding Warrants, Outstanding at Ending Weighted- Average Exercise Price, Outstanding at Ending Aggregate Intrinsic Value, Outstanding at Ending Aggregate Intrinsic Value, Outstanding at Beginning Aggregate Intrinsic Value, Outstanding at Ending Issuance of Series A-1 Preferred Stock [Abstract] Issuance of Series B-1 Preferred Stock and Series B-2 Preferred Stock [Abstract] Warrant Liability [Abstract] Measurement Input Type [Axis] Vesting [Axis] Statistical Measurement [Axis] Number of Shares Underlying Outstanding Warrants, Outstanding at Beginning Number of Shares Underlying Outstanding Warrants, Outstanding at Ending Weighted- Average Exercise Price, Outstanding at Beginning Weighted- Average Exercise Price, Outstanding at Ending Class of Warrant or Right [Axis] Stock-Based Compensation [Abstract] Number of Shares Underlying Outstanding Options Ending (in Shares) Weighted-Average Exercise Price Ending (in Dollars per share) Aggregate Intrinsic Value Ending Derivative Instrument [Axis] Statement of Income [Axis] Net Income (Loss) Per Share [Abstract] Schedule of Basic and Diluted Net Loss Per Share [Abstract] Antidilutive Securities [Axis] Subsequent Events [Abstract] Assets Current assets: Cash and cash equivalents Marketable securities Total marketable securities at fair value Right of use asset, net Liabilities and stockholders’ equity Current liabilities: Operating lease liability - current Less current portion Operating lease liability – long term Long term portion Commitments and contingencies (Note 7) Stockholders’ equity: Preferred stock, value Investors of convertible preferred stock Preferred stock, par value (in Dollars per share) Preferred stock, shares authorized (in Shares) Designated shares Preferred stock, shares outstanding (in Shares) Preferred stock outstanding Preferred stock, shares issued (in Shares) Preferred stock shares issued Common stock, $0.001 par value per share – 400,000,000 shares authorized at December 31, 2025, and March 31, 2026; 22,114,245 and 25,237,782 shares issued and outstanding at December 31, 2025, and March 31, 2026, respectively Common stock, par value (in Dollars per share) Common stock, shares authorized (in Shares) Common stock, shares authorized Common stock, shares issued (in Shares) Common stock share issued Common stock shares issued Common stock, shares outstanding (in Shares) Accumulated other comprehensive (loss) income Additional paid-in capital Accumulated deficit Operating expenses: Research and development General and administrative Other income (expenses): Interest income Other comprehensive loss: Unrealized loss on marketable securities, net Net comprehensive income (loss) attributable to common stockholders, basic Net income (loss) attributable to common stockholders, basic Net comprehensive loss attributable to common stockholders, diluted Net loss attributable to common stockholders, diluted Net comprehensive income (loss) per share Basic (in Dollars per share) Net income (loss) per share attributable to common stockholders, basic (in Dollars per share) Diluted (in Dollars per share) Net loss per share attributable to common stockholders, diluted (in Dollars per share) Weighted-average shares outstanding used in computing net comprehensive income (loss) per share: Denominator: Basic (in Shares) Weighted-average shares outstanding used in computing net income (loss) per share attributable to common stockholders, basic (in Shares) Diluted (in Shares) Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, diluted (in Shares) Conversion of Series A-2 Prime preferred stock into common stock Conversion of Series A-2 Prime preferred stock into common stock (in Shares) Shares of common stock Auto-conversion preferred shares Issuance of common stock for cash, net of issuance costs Common stock valued Issuance of common stock for cash, net of issuance costs (in Shares) Issued of common shares (in Shares) Share issued Stock-based compensation expense Unrealized gain on available-for-sale securities, net Cash flows from operating activities Adjustments to reconcile net loss to net cash used in operating activities: Depreciation expense Stock-based compensation expense Change in fair value of warrant liability Change in fair value of warrant liability Change in fair value of warrants Amortization of operating lease right of use asset Amortization of right-of-use asset Amortization of investments in marketable securities Changes in assets and liabilities: Accounts payable and accrued liabilities Operating lease liability Net cash used in operating activities Cash flows from investing activities Cash flows from financing activities Gross proceeds from secondary public offering Supplemental cash flow information Initial recognition of right-of-use assets and corresponding lease liabilities Deferred insurance charges included in prepaid expenses and other current assets Deferred preclinical and other charges included in prepaid expenses and other current assets Cash paid for interest Interest expense Loss on disposal of assets Prepaid expense and other current assets Purchases of marketable securities Purchases of property and equipment Realized gain on marketable securities Commissions paid on secondary public offering Payments on financed insurance policies Series A-2 Prime Preferred Stock Series A-2 Preferred Stock [Member] Series A-2 Prime Preferred Stock [Member] Series B-2 Preferred Stock Series B-2 Preferred Stock [Member] Common Stock Common Stock [Member] Series A-2 Prime Preferred Stock Series A-2 Prime Preferred Stock [Member] Additional Paid-In Capital Accumulated Deficit Comprehensive Income (Loss) Organization and Description of Business Summary of Significant Accounting Policies Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis Total cash and cash equivalents at fair value Total liabilities at fair value Schedule of Changes in Fair Value of the Warrant Liability Classified in Level 3 Cash, Cash Equivalents, and Marketable Securities Schedule of Company’s Investments Amortized Cost Basis Unrealized Gains Estimated Fair Value Significant Agreements Balance Sheet Components Schedule of Prepaid Expenses and Other Current Assets Prepaid directors’ and officers’ liability insurance premiums Prepaid drug manufacturing supply costs Other Schedule of Property and Equipment Subtotal Schedule of Accounts Payable Trade accounts payable Credit card liability Schedule of Accrued Liabilities Accrued labor costs Accrued drug development costs Other